The efficacy of HPV vaccine to reduce HIV infection (EVRI) trial in the Western Cape, South Africa, enrolled and randomized women 16–24 years to receive human papillomavirus (HPV) vaccination or placebo (with an option for the vaccine in seven months). The extraordinary prevalence of any and high-risk HPV types, and the persistence of high-risk types in both groups, stresses the importance of still earlier vaccination in populations with a large burden of HPV and associated morbidities.
Cervical HPV natural history among young Western Cape, South African women: The randomized control EVRI Trial
Written By
Sundenga SL, Torres BN, Botha MH, Zeier M, Abrahamsen ME, Glashoff RH, Engelbrecht S, Schim Van der Loeff MF, Van der Laan LE, Kipping S, Taylor D, Giuliano AR.
